Intravascular Research Ltd. v. Endosonics Corp.

994 F. Supp. 564, 1998 U.S. Dist. LEXIS 2130, 1998 WL 84411
CourtDistrict Court, D. Delaware
DecidedFebruary 13, 1998
DocketCIV. A. 97-533 MMS
StatusPublished
Cited by2 cases

This text of 994 F. Supp. 564 (Intravascular Research Ltd. v. Endosonics Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Intravascular Research Ltd. v. Endosonics Corp., 994 F. Supp. 564, 1998 U.S. Dist. LEXIS 2130, 1998 WL 84411 (D. Del. 1998).

Opinion

OPINION

SCHWARTZ, Senior District Judge.

I. Introduction

Intravascular Research Ltd. (“IRL”), a United Kingdom company located in Isle-worth, England, brought this action against Endosonics Corporation (“Endosonics”), a Delaware corporation with its princijpal place of business in Sacramento County, California. IRL filed three counts: Count I alleges Endosonics has infringed IRL’s U.S. Patent No. 5,590,659 (“ ’659 Patent”), Count II seeks a declaration of non-infringement with respect to Endosonics U.S. Patent No. 4,917,097 (“’097 Patent”), and Count III requests a declaratory judgment that IRL has not misappropriated any trade secrets of Endoson-' ics, or breached any confidences of Endosonics.

IRL and Endosonics are also involved in a state court proceeding in the Superior Court of the State of California for the County of Sacramento (“the California action”). California Complaint, Docket Item (“ D.I.”) 10, Exhibit 1. In that case, Endosonics sued IRL for misappropriation of trade secrets and breach of confidence. Endosonics seeks a constructive trust in favor of Endosonics on all IRL patent applications and issued patents world-wide based on alleged misappropriated Endosonics technologies, and a court order requiring IRL to assign all their rights in any such applications and issued patents to Endosonics.

Pending before the Court is Endosonics’ motion: 1) to stay all proceedings with respect to Count I pursuant to the Colorado River doctrine pending determination of the ownership of the ’659 Patent in the California state court action and to 2) dismiss Count III as a second-filed, reactive suit in the exercise of the Court’s discretion under the Declaratory Judgment Act, 28 U.S.C. § 2201(a) 1 , 2 The Court has jurisdiction over this case under 28 U.S.C. § 1338(a) and (b). For reasons which follow, the motion to stay Count I of the Complaint will be denied and the motion to dismiss Count III of the Complaint will be granted.

II. Factual Background

Both IRL and Endosonics develop intravascular ultrasound (“IVUS”) imaging systems and apparatus. An IVUS permits a cardiologist to use a specifically-modified catheter to view the inside of the walls of the patient’s blood vessels and other small body cavities. The IVUS images can be employed as a useful diagnostic tool to treat heart disease and other ailments. Currently, Endosonics is'the only company in the United States to manufacture and market an IVUS catheter incorporating this ultrasound technology. IRL is in the process of developing a similar product, and plans to market its technology in United' States and Europe in the near future.

*567 In the summer of 1994, an IRL executive, Dr. Rothman, and an independent consultant working with IRL, Dr. Keilman, visited Endosonics on several occasions for the purpose of discussing a strategic technological and marketing alliance between Endosonics, IRL, and another company. At these visits, Endosonies disclosed details of two of its proprietary technologies: a “flex circuit” design for transducer assemblies and an improved method of performing IVUS imaging called “CDS imaging”. Endosonics maintains these disclosures were made to Drs. Rothman and Keilman under circumstances giving rise to a duty to maintain the disclosed information as confidential and neither reveal it to any other person, nor use it for the benefit of anyone other than Endosonics. Endosonics asserts that three months after the last visit by Drs. Rothman and Keilman, IRL filed separate patent applications in the United Kingdom describing and claiming “flex circuit” and “CDS imaging” technologies similar to those disclosed by Endosonics to the IRL representatives, In addition, Endosonics contends that IRL has since filed patent applications based in whole or in part on these misappropriated technologies in the European Union and elsewhere in the world, including the United States. The “CDS imaging” application already has issued in the United States as the ’659 Patent. Lastly, Endosonics maintains that IRL is now using the misappropriated Endosonics technology to develop a competing IVUS product.

On August 28, 1997, Endosonics sued IRL in the Superior Court of the State of California for the County of Sacramento alleging trade secret misappropriation under the California Trade Secret Act, CAL. CIV. CODE § 3426 et. seq. (West 1993), and breach of confidence under California common law. In the state action, Endosonics has requested the imposition of a constructive trust in favor of Endosonics on all IRL patent applications and issued patents worldwide based on misappropriated Endosonics “flex circuit” and “CDS imaging” technologies, including the ’659 Patent which is the subject of Count I of this federal action, and requested an order requiring IRL to assign all rights to any such applications and issued patents to Endosonics.

On September 19, 1997, IRL filed this patent infringement action. On December 2, 1997, the California state court denied IRL’s motion to stay Endosonics’ state action in light of this federal proceeding. In addition, the state court has assigned the case to a fast-track program, under which the case must be listed for trial in 12 to 18 months. Endosonics has yet to file an answer to the federal complaint lodged against it. 3

III. Discussion

The Court will first address the motion to stay Count I and then will turn its attention to the motion to dismiss Count III.

A. Motion to Stay Count I of the Complaint

1. Which Circuit Court of Appeals’ Law Should Apply

As a preliminary matter, the Court must determine what circuit court of appeals’ law applies to Count I of the Complaint. To determine whether the Federal Circuit Court of Appeals 4 would apply its own law or the *568 law of the Third Circuit Court of Appeals, the Court asks: “whether the law that must be applied, whether procedural or substantive, is one ‘ . over which this court does not have exclusive appellate jurisdiction.’” See Biodex Corp. v. Loredan Biomedical, Inc., 946 F.2d 850, 855-56 (Fed.Cir.1991), cert. denied, 504 U.S. 980, 112 S.Ct. 2957, 119 L.Ed.2d 579 (1992) (quoting in part Cicena Ltd. v. Columbia Telecomm. Group, 900 F.2d 1546, 1548 .(Fed.Cir.1990)); see also Beverly Hills Fan Co. v. Royal Sovereign Corp., 21 F.3d 1558, 1564 (Fed.Cir.) (“[W]e apply the law of the [regional circuit] to procedural matters that are not unique to patent law.”), cert.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Foxfield Villa Associates, LLC v. Regnier
918 F. Supp. 2d 1192 (D. Kansas, 2013)
Applera Corp.-Applied Biosystems Group v. Illumina, Inc.
282 F. Supp. 2d 1120 (N.D. California, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
994 F. Supp. 564, 1998 U.S. Dist. LEXIS 2130, 1998 WL 84411, Counsel Stack Legal Research, https://law.counselstack.com/opinion/intravascular-research-ltd-v-endosonics-corp-ded-1998.